Medha Singh

Medha Singh

Auto-generated profile, based on publicly available information

Medha Singh

Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
XCXueyi Chen
Xueyi Chen
CRCarlos E Ruiz-Gonzalez
Carlos E Ruiz-Gonzalez
YMYuderleys Masias-Leon
Yuderleys Masias-Leon
MSMedha Singh
Medha Singh
ONOscar J Nino-Meza
Oscar J Nino-Meza
SJSanjay Jain
Sanjay Jain
Tuberculous meningitis (TB meningitis), the most severe form of tuberculosis, carries high mortality and neurological sequelae, and current rifampin-based regimen are limited by poor central nervous system penetration. Alternative rifamycins like rifapentine and rifabutin, with different pharmacokinetic profiles, are effective for treating drug-susceptible pulmonary tuberculosis, with rifapentine now forming the basis of a World Health Organization-approved 4-month daily rifapentine-moxifloxacin regimen, and retrospective studies showing that rifabutin-based regimens are effective and well tolerated, however, both drugs still need dedicated evaluation in TB meningitis. Mice were intracranially inoculated with Mycobacterium tuberculosis and treated with rifamycin (rifampin, rifapentine, or rifabutin)-based regimens at human equipotent doses. We assessed the bactericidal activities of the 3 regimens, rifamycin tissue concentrations, brain inflammation (brain magnetic resonance imaging, tissue immunofluorescence, cytokines), and neuronal injury. Both rifapentine- and rifabutin-containing regimens demonstrated bactericidal activity in the brain, similar to or better than the standard rifampin-containing regimen, as well as reduced neuroinflammation and brain injury. Alternate rifamycins, rifapentine and rifabutin, show therapeutic activity and neuroprotective effects, supporting their evaluation in clinical trials for treating TB meningitis.

23 February 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
XCXueyi Chen
Xueyi Chen
CRCarlos E Ruiz-Gonzalez
Carlos E Ruiz-Gonzalez
YMYuderleys Masias-Leon
Yuderleys Masias-Leon
MSMedha Singh
Medha Singh
CPCharles A Peloquin
Charles A Peloquin
SJSanjay Jain
Sanjay Jain
Tuberculous meningitis causes substantial mortality due to limited penetration of antibiotics to the central nervous system and excessive neuroinflammation. This study evaluated clofazimine as an adjunct to the standard first-line tuberculosis regimen, in a mouse model. Mice were infected intracerebrally with Mycobacterium tuberculosis and treated for 6 weeks. Addition of clofazimine markedly reduced the brain bacterial burden, achieving measurable brain tissue concentrations despite minimal cerebrospinal fluid penetration, as well as attenuated brain tissue inflammation. These findings indicate that clofazimine enhances bactericidal activity of the standard regimen and mitigate neuroinflammation, supporting further investigation and clinical evaluation for tuberculous meningitis.